Powered by

Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring

May 04, 2017 - PR Newswire
Board and Executive Moves-Financial Results

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the three months ended March 31, 2017.  The Company also announced a corporate restructuring plan to streamline its operations as it focuses on its most promising discovery and development programs.

The restructuring includes an immediate workforce reduction of approximately 30%, which is expected to ...